<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p75" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_75{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_75{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_75{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_75{left:715px;bottom:1115px;letter-spacing:-0.01px;}
#t5_75{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t6_75{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t7_75{left:238px;bottom:1022px;letter-spacing:-0.01px;}
#t8_75{left:238px;bottom:1003px;letter-spacing:-0.01px;}
#t9_75{left:238px;bottom:983px;letter-spacing:-0.01px;}
#ta_75{left:293px;bottom:948px;}
#tb_75{left:321px;bottom:948px;letter-spacing:-0.01px;}
#tc_75{left:321px;bottom:929px;letter-spacing:-0.01px;}
#td_75{left:321px;bottom:909px;letter-spacing:-0.01px;}
#te_75{left:321px;bottom:890px;letter-spacing:-0.01px;}
#tf_75{left:293px;bottom:869px;}
#tg_75{left:321px;bottom:870px;letter-spacing:-0.01px;}
#th_75{left:293px;bottom:849px;}
#ti_75{left:321px;bottom:850px;letter-spacing:-0.01px;}
#tj_75{left:321px;bottom:830px;letter-spacing:-0.01px;}
#tk_75{left:293px;bottom:810px;}
#tl_75{left:321px;bottom:810px;letter-spacing:-0.01px;}
#tm_75{left:321px;bottom:791px;letter-spacing:-0.01px;}
#tn_75{left:293px;bottom:771px;}
#to_75{left:321px;bottom:771px;letter-spacing:-0.01px;}
#tp_75{left:321px;bottom:752px;letter-spacing:-0.01px;}
#tq_75{left:293px;bottom:731px;}
#tr_75{left:321px;bottom:732px;letter-spacing:-0.01px;}
#ts_75{left:321px;bottom:712px;letter-spacing:-0.01px;}
#tt_75{left:293px;bottom:692px;}
#tu_75{left:321px;bottom:692px;letter-spacing:-0.01px;}
#tv_75{left:321px;bottom:673px;letter-spacing:-0.01px;}
#tw_75{left:321px;bottom:653px;letter-spacing:-0.01px;}
#tx_75{left:321px;bottom:634px;letter-spacing:-0.01px;}
#ty_75{left:293px;bottom:594px;}
#tz_75{left:321px;bottom:595px;letter-spacing:-0.01px;}
#t10_75{left:293px;bottom:574px;}
#t11_75{left:321px;bottom:575px;letter-spacing:-0.01px;}
#t12_75{left:293px;bottom:535px;}
#t13_75{left:321px;bottom:535px;letter-spacing:-0.01px;}
#t14_75{left:293px;bottom:515px;}
#t15_75{left:321px;bottom:515px;letter-spacing:-0.01px;}
#t16_75{left:238px;bottom:487px;letter-spacing:-0.01px;}
#t17_75{left:238px;bottom:467px;letter-spacing:-0.01px;}
#t18_75{left:293px;bottom:438px;}
#t19_75{left:321px;bottom:438px;letter-spacing:-0.01px;}
#t1a_75{left:293px;bottom:418px;}
#t1b_75{left:321px;bottom:418px;letter-spacing:0.11px;}
#t1c_75{left:293px;bottom:398px;}
#t1d_75{left:321px;bottom:398px;letter-spacing:-0.01px;}
#t1e_75{left:321px;bottom:379px;letter-spacing:-0.01px;}
#t1f_75{left:321px;bottom:359px;letter-spacing:-0.01px;}
#t1g_75{left:321px;bottom:340px;letter-spacing:-0.01px;}
#t1h_75{left:293px;bottom:320px;}
#t1i_75{left:321px;bottom:320px;letter-spacing:-0.01px;}
#t1j_75{left:293px;bottom:300px;}
#t1k_75{left:321px;bottom:300px;letter-spacing:-0.01px;}
#t1l_75{left:293px;bottom:280px;}
#t1m_75{left:321px;bottom:280px;letter-spacing:-0.01px;}
#t1n_75{left:293px;bottom:260px;}
#t1o_75{left:321px;bottom:260px;letter-spacing:-0.01px;}
#t1p_75{left:293px;bottom:240px;}
#t1q_75{left:321px;bottom:240px;letter-spacing:-0.01px;}
#t1r_75{left:293px;bottom:220px;}
#t1s_75{left:321px;bottom:220px;letter-spacing:-0.01px;}
#t1t_75{left:321px;bottom:201px;letter-spacing:-0.01px;}
#t1u_75{left:321px;bottom:181px;letter-spacing:-0.01px;}
#t1v_75{left:293px;bottom:161px;}
#t1w_75{left:321px;bottom:161px;letter-spacing:-0.01px;}
#t1x_75{left:321px;bottom:142px;letter-spacing:-0.01px;}
#t1y_75{left:293px;bottom:121px;}
#t1z_75{left:321px;bottom:122px;letter-spacing:-0.01px;}
#t20_75{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_75{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_75{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_75{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_75{font-size:13px;font-family:NotoSans-Regular_7j-_1;color:#000;}
.s4_75{font-size:14px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_75{font-size:12px;font-family:NotoSans-Regular_7j-_1;color:#000;}
.s6_75{font-size:11px;font-family:NotoSans-Regular_7j-_1;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts75" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

@font-face {
	font-family: NotoSans-Regular_7j-_1;
	src: url("fonts/NotoSans-Regular_7j-_1.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg75Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg75" style="-webkit-user-select: none;"><object width="908" height="1286" data="75/75.svg" type="image/svg+xml" id="pdf75" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_75" class="t s0_75">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_75" class="t s1_75">75 </span>
<span id="t3_75" class="t s2_75">In the DeLOS-II study, the stage assessment is expanded to T4a “low volume”, </span><span id="t4_75" class="t s3_75">i.e. with a </span>
<span id="t5_75" class="t s3_75">total metastasis volume of &lt; 80 ml. Laryngeal cartilage infiltration is permitted, but the </span>
<span id="t6_75" class="t s3_75">laryngeal cartilage must not be perforated to the outside. </span>
<span id="t7_75" class="t s3_75">Patients who meet all of the following criteria are in principle suitable for multimodal </span>
<span id="t8_75" class="t s3_75">organ preservation protocols (radiation + taxane- or platinum-based chemotherapy) as </span>
<span id="t9_75" class="t s3_75">an alternative to laryngectomy: </span>
<span id="ta_75" class="t s4_75">• </span><span id="tb_75" class="t s3_75">Histologically proven squamous cell carcinoma of the larynx or hypopharynx that </span>
<span id="tc_75" class="t s3_75">can only be resected by laryngectomy (the possibility of organ-preserving partial </span>
<span id="td_75" class="t s3_75">laryngeal resection should always be intensively examined and weighed up within </span>
<span id="te_75" class="t s3_75">the framework of existing local expertise): </span>
<span id="tf_75" class="t s4_75">• </span><span id="tg_75" class="t s3_75">T3-T4a glottic carcinomas </span>
<span id="th_75" class="t s4_75">• </span><span id="ti_75" class="t s3_75">T2-T4a supraglottic carcinomas that can only be managed by laryngectomy and </span>
<span id="tj_75" class="t s3_75">possibly resection of the base of the tongue </span>
<span id="tk_75" class="t s4_75">• </span><span id="tl_75" class="t s3_75">T2-T4a hypopharyngeal carcinomas that can only be managed by </span>
<span id="tm_75" class="t s3_75">laryngectomy (e.g. T2, postcricoidal) and partial hypopharyngeal resection </span>
<span id="tn_75" class="t s4_75">• </span><span id="to_75" class="t s3_75">N-Status: Cervical metastases (N0-N3) must be remediable by standardized </span>
<span id="tp_75" class="t s3_75">surgical procedures </span>
<span id="tq_75" class="t s4_75">• </span><span id="tr_75" class="t s3_75">Blood count: leukocytes &gt; 3,500/mm3 or neutrophils &gt; 1,500/mm3, </span>
<span id="ts_75" class="t s3_75">platelets &gt; 80,000/mm3 </span>
<span id="tt_75" class="t s4_75">• </span><span id="tu_75" class="t s3_75">Laboratory: adequate renal function, defined as serum creatinine and urea not </span>
<span id="tv_75" class="t s3_75">more than 25% above normal range, creatinine clearance &gt; 60 ml/min/1.72 m2; </span>
<span id="tw_75" class="t s3_75">adequate liver function with SGOT, SGPT not more than 50% and bilirubin not </span>
<span id="tx_75" class="t s3_75">above normal range; electrolytes within normal range </span>
<span id="ty_75" class="t s4_75">• </span><span id="tz_75" class="t s3_75">Anaesthesia risk normal to slightly increased </span>
<span id="t10_75" class="t s4_75">• </span><span id="t11_75" class="t s3_75">Willingness to undergo salvage surgery if there is no response </span>
<span id="t12_75" class="t s4_75">• </span><span id="t13_75" class="t s3_75">Possibility and willingness to undergo close tumor follow-up </span>
<span id="t14_75" class="t s4_75">• </span><span id="t15_75" class="t s3_75">In principle no age restriction </span>
<span id="t16_75" class="t s3_75">Patients who meet any of the following criteria are not eligible for multimodal organ </span>
<span id="t17_75" class="t s3_75">preservation protocols: </span>
<span id="t18_75" class="t s4_75">• </span><span id="t19_75" class="t s3_75">Primary tumor can be treated by larynx-preserving surgical procedures </span>
<span id="t1a_75" class="t s4_75">• </span><span id="t1b_75" class="t s5_75">Distant metastases (M1 status) </span>
<span id="t1c_75" class="t s4_75">• </span><span id="t1d_75" class="t s3_75">Primary tumor volume greater than 14 ml and total tumor volume greater than 80 </span>
<span id="t1e_75" class="t s3_75">ml or laryngeal skeleton breached with infiltration of the surrounding soft tissues </span>
<span id="t1f_75" class="t s3_75">or the esophageal entrance (cartilage infiltration alone is not an exclusion </span>
<span id="t1g_75" class="t s2_75">criterion) </span>
<span id="t1h_75" class="t s4_75">• </span><span id="t1i_75" class="t s3_75">Tumor-specific pretreatment with chemotherapy or radiotherapy </span>
<span id="t1j_75" class="t s4_75">• </span><span id="t1k_75" class="t s3_75">Life expectancy less than 3 months </span>
<span id="t1l_75" class="t s4_75">• </span><span id="t1m_75" class="t s3_75">Karnofsky performance status &lt; 60% </span>
<span id="t1n_75" class="t s4_75">• </span><span id="t1o_75" class="t s3_75">acute infections or fever </span>
<span id="t1p_75" class="t s4_75">• </span><span id="t1q_75" class="t s3_75">known HIV infection or other immunosuppression </span>
<span id="t1r_75" class="t s4_75">• </span><span id="t1s_75" class="t s3_75">severe cardiopulmonary concomitant diseases (heart failure grade III and IV </span>
<span id="t1t_75" class="t s3_75">according to NYHA status, myocardial infarction, angina pectoris, global </span>
<span id="t1u_75" class="t s3_75">respiratory failure) </span>
<span id="t1v_75" class="t s4_75">• </span><span id="t1w_75" class="t s3_75">Chronic diseases requiring long-term therapy (uncontrolled diabetes, active </span>
<span id="t1x_75" class="t s3_75">rheumatoid arthritis) </span>
<span id="t1y_75" class="t s4_75">• </span><span id="t1z_75" class="t s3_75">Expected lack of patient compliance </span>
<span id="t20_75" class="t s6_75">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
